DF
IOVA icon

Dunhill Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Dunhill Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14 Hold
3
– – ﹤0.01% 1602
2026
Q1 		$11 Hold
3
– – ﹤0.01% 1821
2025
Q4 		$9 Buy
+3
New +$7 ﹤0.01% 1991
2024
Q4 		– Sell
-1,100
Closed -$10.3K – 945
2024
Q3 		$10.3K Sell
1,100
-30
-3% -$284 0.01% 375
2024
Q2 		$9.06K Buy
1,130
+1,100
+3,667% +$11.8K 0.01% 314
2024
Q1 		$445 Hold
30
– – ﹤0.01% 715
2023
Q4 		$244 Buy
+30
New +$157 ﹤0.01% 713

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Dunhill Financial's IOVA Position: Q2 2026 in Review

Dunhill Financial held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 3 shares worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

Dunhill Financial first reported a position in IOVA in Q4 2023 and has held it in 7 quarters since. The position peaked at $10.3K in Q3 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Dunhill Financial held 3 shares of Iovance Biotherapeutics worth $14 as of Q2 2026.
  • Dunhill Financial left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1602 holding.
  • Dunhill Financial first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 7 quarters since.
  • Dunhill Financial's Iovance Biotherapeutics position peaked at $10.3K in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.